雜志介紹

Cancer Cell雜志介紹

《Cancer Cell》是一本以English為主的未開放獲取國際優秀期刊，中文名稱癌細胞，本刊主要出版、報道醫學-CELL BIOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為48.8，最新CiteScore 指數為55.2。

本刊近期中國學者發表的論文主要有：

• Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer

  Author: Teng, Huajing; Wang, Yan; Sui, Xin; Fan, Jiawen; Li, Shuai; Lei, Xiao; Shi, Chen; Sun, Wei; Song, Maxiaowei; Wang, Hongzhi; Dong, Dezuo; Geng, Jianhao; Zhang, Yangzi; Zhu, Xianggao; Cai, Yong; Li, Yongheng; Li, Bo; Min, Qingjie; Wang, Weihu; Zhan, Qimin

• A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK

  Author: Xiaodong Feng, Nadia Arang, Damiano Cosimo Rigiracciolo, Joo Sang Lee, Huwate Yeerna, Zhiyong Wang, Simone Lubrano, Ayush Kishore, Jonathan A. Pachter, Gabriele M. K?nig, Marcello Maggiolini, Evi Kostenis, David D. Schlaepfer, Pablo Tamayo, Qianming Chen, Eytan Ruppin, J. Silvio Gutkind

• Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation

  Author: Jinchul Kim, Lili Yu, Wancheng Chen, Yanxia Xu, Meng Wu, Dilyana Todorova, Qingshuang Tang, Bingbing Feng, Lei Jiang, Jingjin He, Guihua Chen, Xuemei Fu, Yang Xu

• CHAF1B Overexpression: A Brake for the Differentiation of Leukemia Cells

  Author: Qing Li, Xu Zhang, Zhiguo Zhang

英文介紹

Cancer Cell雜志英文介紹

Cancer Cell provides a high-profile forum to promote major advances in cancer research and oncology. The primary criterion for considering manuscripts is whether the studies provide major advances into answering important questions relevant to naturally occurring cancers. Cancer Cell particularly welcomes translational research. Cancer Cell is also interested in publishing clinical investigations, in particular those that lead to establishing new paradigms in the treatment, diagnosis, or prevention of cancers; those that provide important insights into cancer biology beyond what has been revealed by preclinical studies; and those that are mechanism-based proof-of-principle clinical studies.